Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Canagliflozin (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms COMETA
- Sponsors Janssen Research & Development
- 12 Jul 2018 Planned End Date changed from 29 Jun 2018 to 30 Sep 2018.
- 12 Jul 2018 Planned primary completion date changed from 30 Mar 2018 to 1 Sep 2018.
- 15 Nov 2017 Status changed from not yet recruiting to recruiting.